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Abstract 
Huntington’s disease (HD) is a hereditary disorder caused by a mutation in the exon-1 
of the IT-15 gene, which encodes for a protein called huntingtin. The N-terminal region of 
mutant huntingtin is prone to aggregate and is toxic for specific types of neurons in the 
striatum and cortex, leading to the involuntary movements and psychiatric disturbances that 
characterize HD. Growing evidence indicates that the smaller, more soluble aggregates 
(dimers and oligomers) are the most toxic species, but little is still known about the process of 
huntingtin oligomerization. 
The aim of this thesis was to elucidate the role of the N-terminal region of huntingtin 
on its oligomerization, aggregation and toxicity. We put special emphasis on its 
phosphorylatable residues (T3, S13 and S16), because phosphorylation pathways are involved 
in key aspects of HD. We used a huntingtin-Venus bimolecular fluorescence 
complementation (BiFC) assay recently developed in our laboratory. In this model, huntingtin 
exon-1 is fused to two non-fluorescent halves of the Venus protein (V1 and V2). When 
huntingtin dimerizes, the two halves get together and reconstitute the functional fluorophore. 
We used these BiFC constructs to create a series of phosphoresistant (T3A, S13A, S16A) and 
phosphomimic (T3D, S13D, S16D) huntingtin mutants and test their behavior in living cells. 
The presence of phosphomimic mutations in both 103QHtt-V1 and 103QHtt-V2 BiFC 
constructs completely abolished the generation of huntingtin aggregates. Combinations of a 
non-mutated construct with a phosphomimic construct produced intermediate phenotypes in 
terms of oligomerization and aggregation. Phosphoresistant BiFC pairs did not produce overt 
phenotypes. Mutations in N-terminal residues had varied effects on Htt toxicity, which 
apparently were not associated with the levels of oligomeric species or inclusion bodies.   
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Our results contribute to a better understanding of HD and highlight the therapeutic 
potential of targeting the phosphorylatable residues of N-terminal huntingtin. 
Keywords: Huntington’s disease; huntingtin; oligomeric species; phosphorylation; 
BiFC system. 
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Resumo 
A doença de Huntington (HD) é uma doença hereditária causada por uma mutação no 
exão-1 do gene IT-15, que codifica para a proteína huntingtina. A região N-terminal da 
proteína mutada tem tendência para agregar e é tóxica para tipos específicos de neurónios no 
estriado e no córtex, levando ao aparecimento de movimentos involuntários e perturbações 
psiquiátricas, que caracterizam a doença. Evidências crescentes indicam que os agregados 
mais pequenos e solúveis (dímeros e oligomeros) representam as espécies mais tóxicas, no 
entanto, pouco se sabe acerca do processo de oligomerização da huntingtina.  
O principal objectivo deste trabalho foi elucidar o papel da região N-terminal da 
huntingtina na sua oligomerização, agregação e toxicidade. Focámo-nos especialmente nos 
resíduos fosforiláveis (T3, S13 e S16), uma vez que as vias de fosforilação estão envolvidas 
em aspectos-chave da HD. Foi utilizado um sistema de complementação bimolecular de 
fluorescência(BiFC), recentemente desenvolvido no nosso laboratório. Neste modelo, o exão-
1 da huntingtina é fundido com duas metades não fluorescentes da proteína Venus(V1 e V2). 
Quando a huntingina dimeriza, as duas metades unem-se, reconstituindo o fluoróforo 
funcional. Estas ferramentas BiFC foram utilizadas para criar vários mutantes resistentes à 
fosforilação (T3A, S13A, S16A) e constitutivamente fosforilados (T3D, S13D, S16D), sendo 
o seu comportamento testado em células vivas. Quando presentes em ambas as metades 
103QHtt-V1 e 103QHtt-V2 BiFC, as mutações que imitam a fosforilação, resultaram na 
abolição de agregados nas células. Combinações de metades BiFC mutadas e não-mutadas 
produziram fenótipos mistos em termos de oligomerização e agregação. Mutantes BiFC 
resistentes à fosforilação não produziram fenótipos evidentes. As mutações nos resíduos da 
região N-terminal evidenciaram efeitos diversos na toxicidade da huntingtina, aparentemente 
não associados com os níveis de oligomeros ou agregados. 
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Os nossos resultados contribuem para uma melhor compreensão da HD, destacando o 
potencial alvo terapêutico dos resíduos fosforiláveis da região N-terminal da huntingtina. 
Palavras-chave: Doença de Huntington; huntingtina; espécies oligoméricas; fosforilação; 
sistema BiFC. 
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1. Introduction 
1.1. Huntington’s Disease 
 Huntington’s disease (HD) is a devastating neurodegenerative disorder first described 
by George Huntington in 1872 (Huntington, 1872). HD is caused by an abnormal expansion 
of a triplet cytosine-adenine-guanine (CAG) repeat in an autosomal dominant gene located in 
the short arm of chromosome 4. The worldwide prevalence is approximately 4 to 10 cases per 
100,000 individuals, making it the most common inherited neurodegenerative disorder 
(Imarisio et al., 2008, Landles and Bates, 2004, Roos, 2010).  
HD is characterized by motor, psychiatric and cognitive features. The first described 
symptom is known as chorea or jerky dance-like movements, and consists in involuntary 
movements of facial muscles and distal extremities that gradually extend to other skeletal 
muscles, ultimately affecting the motor control of all body, legs and arms. This inability to 
coordinate muscles is the result of a progressive cell loss in the striatum (caudate nucleus and 
putamen) of the basal ganglia, which primarily affects the medium spiny neurons (Figure 1). 
However, in late stages of the disease, neuronal degeneration extends to other areas of the 
brain, including thalamus and deep layers of the cortex. As a consequence, cognitive, 
behavioural and psychiatric complications emerge, including personality changes, irritability, 
anxiety, depression and dementia. Most HD patients also experience extreme weight loss and 
sleep disturbances (Costa et al., 2003, Kaplan and Stockwell, 2012, Mestre et al., 2009, Roos, 
2010). 
The gene responsible for HD, known as IT-15, is an extremely large 180 kb DNA 
sequence with 67 exons. The pathogenic CAG expansion is found in the first exon of the gene 
and encodes for an abnormally expanded polyglutamine (polyQ) amino acid sequence within 
the N-terminal region of the huntingtin protein (Htt) (Ambrose et al., 1994, The Huntington’s 
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Disease Collaborative Research Group, 1993). In normal conditions, the number of CAG is 
repeated between 6 and 29 times. The disease manifests when this number increases over 36 
repeats. Individuals with 29 to 36 CAG repeats are generally asymptomatic for the disease. 
However, these intermediate alleles are meiotically unstable and tend to expand above 36 
repeats, causing the disorder in future generations especially when transmitted through the 
paternal line (Duyao et al., 1993, Trottier et al., 1994). 
The length of expanded CAG is inversely correlated with the age of onset and directly 
correlated with the severity of the disease, i.e. the higher the number of CAG repeats, the 
earlier symptoms manifest and the more devastating is the disease. HD occurs most frequently 
in midlife, but the clinical symptoms can also appear in children or young adults. The juvenile 
cases of HD carry more than 55 CAG repeats and the disease progresses more rapidly, leading 
to death 11 years after its first manifestation, compared to 15-20 years of a typical adult onset 
(Foroud et al., 1999, Telenius et al., 1993). 
Currently there are no drugs that can alter the course of HD, and available treatments 
act only at a symptomatic level. Additionally, many of the existent drugs have adverse side 
effects that can worsen HD pathology (Martin et al., 2008, Roos, 2010). Thus, a better 
understanding of HD pathogenesis is needed for the development of disease-modifying 
therapeutic strategies that can stop, delay or reverse the progression of HD. 
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Figure 1. Selective neuronal degeneration in HD patient brains. The most common histopathological 
hallmark of HD is the accumulation of intracellular proteinaceous inclusions, which is associated with 
neurotoxicity in specific brain areas. Neuronal loss is primarily found in the neostriatum and cerebral cortex, 
many years before clinical symptoms appear, and marked striatal and cortical atrophy are already present at the 
time of diagnosis. Adapted from http://www.nature.com/nrm/journal/v1/n2/fig_tab/nrm1100_120a_F2.html 
http://medgen.genetics.utah.edu/photographs/pages/huntington.htm and http://marcora.caltech.edu/science.htm 
 
1.2. Huntingtin protein and HD pathogenic mechanisms 
 Htt is an extremely large protein (350 kDa) that is ubiquitously expressed and widely 
distributed throughout all body tissues, included the brain (The Huntington’s Disease 
Collaborative Research Group, 1993). The specific molecular role of normal Htt in neuronal 
and non-neuronal cell types is not well defined (Krobitsch and Kazantsev, 2011), but it plays 
a role as a scaffold protein in intracellular trafficking and signaling pathways (Rockabrand et 
al., 2007, Strehlow et al., 2007, Tukamoto et al., 1997). Htt is also associated with 
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transcription factors (Kegel et al., 2002, Zuccato et al., 2003) and implicated in synaptic 
(Smith et al., 2005) and anti-apoptotic processes (Leavitt et al., 2006, Luo and Rubinsztein, 
2009). Additionally, Htt knockout mice are not viable and die as embryos, suggesting that 
wild-type (wt) Htt is essential for normal development (Duyao et al., 1995, Nasir et al., 1995, 
Zeitlin et al., 1995). 
 The expansion of the polyglutamine tract leads to both a gain of toxic function and a 
loss of normal Htt function (Cisbani and Cicchetti, 2012). Mutant Htt becomes involved in 
various aberrant protein-protein interactions that cause activation of pro-apoptotic proteins 
(Hermel et al., 2004, Yang et al., 2010), mitochondrial dysfunction (Orr et al., 2008, Panov et 
al., 2002), impaired vesicular trafficking (Gauthier et al., 2004, Qin et al., 2004), 
transcriptional dysregulation (Nucifora et al., 2001), excitotoxicity (Heng et al., 2009, Shin et 
al., 2005) and ultimately cell death (Zeron et al., 2001). The precise molecular mechanism of 
such pathological effects of mutant Htt is not clear. However, aberrant oligomerization of Htt 
molecules and their organization into amyloid-like proteinaceous aggregates is considered to 
have a leading role in HD pathogenesis. Htt aggregates are also the most common 
histopathological hallmark of the disease, being observed in neurons of all cortical layers and 
in medium-sized neurons of the striatum (Rochet, 2007). The presence of large amyloid 
inclusions is a feature shared by most neurodegenerative disorders, including many CAG 
repeat disorders such as spinocerebellar ataxias (SCA), spinal bulbar muscular atrophy 
(SBMA) and dentatorubral-pallidoluysian atrophy (DRPLA) (Kaplan and Stockwell, 2012, 
Martin et al., 2008).  
 The intracellular accumulation of mutant Htt is facilitated by its cleavage through 
caspase-mediated proteolytic degradation, which liberates toxic N-terminal fragments 
containing Htt exon 1 (Httex1) (Borrell-Pages et al., 2006). Expression of mutant Httex1 is 
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sufficient to cause the disorder in mice, strongly indicating that this fragment of the protein is 
a key player in HD pathogenesis (Mangiarini et al., 1996). Httex1-containing fragments are 
more prone to misfold and aggregate than full-length mutant Htt (Ross et al., 1999). The 
aggregation of proteolytic Htt fragments is a dynamic process that starts with the dimerization 
of soluble misfolded monomers and progresses towards the formation of small oligomers, 
ultimately leading to the production of larger and more insoluble structures, such as 
protofibrils, fibrils and inclusion bodies (Agorogiannis et al., 2004, Hartl and Hayer-Hartl, 
2009, Zheng and Diamond, 2012, Zuccato et al., 2010) (Figure 2). 
 
Figure 2. Aggregate formation process.  Mutant Htt undergoes covalent modifications, such as cleavage or 
post-translational modifications, leading to conformational changes of the protein. The misfolded protein forms 
soluble oligomer intermediates that can accumulate as a globular structure and further form protofibrils. 
Protofibrils rearrange into amyloid-like structures, ultimately resulting in aggregates or inclusions. The 
aggregates consist of β-sheet-rich fibrils aligned side-by-side to form large insoluble species that were originally 
thought to be neurotoxic. However, several studies postulate that mutant Htt inclusions are not pathogenic but 
rather an attempt of the cells to sequester toxic soluble fragments. Adapted from (Zuccato et al., 2010). 
 
Whether large, insoluble aggregates are toxic or protective species has been 
extensively debated. They were originally thought to be cytotoxic for several reasons. First, 
unlike soluble oligomers, they were clearly and easily observed in post-mortem 
histopathological studies of HD brains (Maat-Schieman et al., 1999, Sapp et al., 1997). 
Second, like the severity of the disease, the formation of large inclusion bodies is directly 
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correlated with polyglutamine repeat length both in vitro and in vivo and with worsening of 
HD clinical features (DiFiglia et al., 1997, Li and Li, 1998). A HD mouse model expressing 
mutant Httex1 showed a strong correlation between mutant Htt inclusions and disease 
progression. The formation of large inclusions was abolished when mutant Htt expression was 
blocked, leading to an amelioration of the behavioral phenotype (Yamamoto et al., 2000). 
And third, the accumulation of mutant Htt fragments has been associated with the failure of 
important cellular and molecular mechanisms for the maintenance of cell viability, such as 
ubiquitin–protease system (UPS) and the chaperone refolding cycles. Proteasome subunits 
and molecular chaperones were found within Htt aggregates, which suggests that misfolded 
Htt fragments are targeted for degradation but the UPS is unable to clear the large 
polyglutamine stretch, leading to its accumulation (Martin et al., 2008, Zuccato et al., 2010). 
Furthermore, overexpression of molecular chaperones, such as heat-shock proteins (Hsps) 70 
and 104, has been shown to prevent the formation of large aggregates, to reduce cell death in 
mammalian cell models of HD and to increase life span in Drosophila and mouse models of 
the disease (Carmichael et al., 2000, Vacher et al., 2005, Warrick et al., 1999). However, 
these chaperones could reduce the number of large inclusions by preventing the formation of 
soluble intermediates, such oligomeric species, and/or by refolding smaller misfolded 
fragments (Imarisio et al., 2008). The same logic can be applied to the rest of the arguments in 
favor of the cytotoxicity of large protein inclusions, because they are always equally 
satisfactory if the toxic species were the oligomeric ones. 
There is now increasing support for the idea that the formation of large aggregates are 
a protective cell mechanism to scavenge more soluble and toxic forms, such as dimers and 
oligomers (Arrasate et al., 2004, Bodner et al., 2006, Kuemmerle et al., 1999). Arrasate et al. 
(2004) showed that cells with large inclusions survived significantly longer than cells with 
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diffuse mutant Htt. Similarly, an in vivo study demonstrated that despite the presence of large 
inclusions in HD mouse brain expressing N-terminal fragments of Htt under the control of the 
endogenous human promoter (shortstop), no clinical evidence of neurodegeneration was 
observed (Slow et al., 2005). In the context of other neurodegenerative disorders, such as 
Parkinson’s and Alzheimer’s disease, oligomers are proven to be the most toxic species due to 
their higher reactivity and their ability to move more freely between cell and tissue 
compartments (Agorogiannis et al., 2004, Taylor et al., 2002). Most research has focused on 
the mechanisms of generation of large aggregates, mainly because they are obvious structures 
in cells and tissues. However, little is known about how smaller intermediate species, such as 
dimers and oligomers, are generated in HD. This is due, at least in part, to the lack of suitable 
experimental models for their visualization and study in living cells until relatively recently 
(Herrera et al., 2011, Lajoie and Snapp, 2010, Outeiro et al., 2008). 
As mentioned above, the generation of N-terminal fragments containing Httex1 is a 
key step in HD pathology, Httex1 being sufficient to cause HD in animal models (Bates et al., 
1998, Mangiarini et al., 1996). Httex1 contains an N-terminal sequence of 17 amino acids 
(NT17 domain) preceding the polyQ tract and a proline-rich region (PRR) (Figure 3). The 
first 17 amino acids of Htt are highly conserved throughout mammalian evolution, suggesting 
an important function of the NT17 domain (Atwal et al., 2007, Rockabrand et al., 2007). This 
domain contains a functionally active nuclear export signal (NES) that is responsible for the 
cytosolic localization of Htt, and the expansion of polyglutamine repeat or the removal of 
these amino acids lead to Htt nuclear accumulation (Cornett et al., 2005, Xia et al., 2003). 
Cornett et al. (2005) showed that the NT17 sequence binds to the nuclear pore protein Tpr, 
which exports proteins from the nucleus. Furthermore, the NT17 domain forms an 
amphipathic alpha helical membrane-binding domain that can reversibly target Htt to 
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mitochondria, endosomes and autophagic vesicules, Golgi apparatus and endoplasmic 
reticulum (ER) (Atwal et al., 2007, Rockabrand et al., 2007). This domain also plays an 
important role in mutant Htt aggregation, since it can interact with the adjacent polyQ region, 
influencing each other’s structure and the aggregation properties of mutant Htt (Thakur et al., 
2009, Williamson et al., 2010). Moreover, deletion or particular post-translational 
modifications of NT17, such as SUMOylation (Steffan et al., 2004), ubiquitination (Jana et 
al., 2005, Zucchelli et al., 2011), acetylation (Steffan et al., 2001) and phosphorylation (Aiken 
et al., 2009, Gu et al., 2009, Thompson et al., 2009), modulate the propensity of mutant Htt to 
form aggregates and its subcellular localization, clearance and toxicity. 
The PRR, directly following the polyQ region, is a sequence of approximately 50 
amino acids that comprises a stretch of 11 consecutive proline residues, followed by several 
mixed proline/glutamine residues with 7 scattered proline residues, and then another proline-
enriched tract containing 10 consecutive prolines (Kaplan and Stockwell, 2012, Neveklovska 
et al., 2012). PRR can stabilize the structure of the polyQ stretch and is proposed to be 
involved in the interaction of Htt with several partners (Borrell-Pages et al., 2006, Kaplan and 
Stockwell, 2012). However, it does not seem to have a direct role in HD pathology. A very 
recent in vivo study showed that mice expressing huntingtin without PRR are born at normal 
frequency and develop normal motor function, coordination and balance, which suggests that 
PRR is not required for normal Htt function (Neveklovska et al., 2012). 
 
1.3. Phosphorylation pathways involved in HD pathogenesis 
 The reversible addition of a phosphate group to amino acids containing an extra 
carboxyl residue (Serine, Threonine and Tyrosine) by kinases, or the inverse reaction 
catalyzed by phosphatases, can modulate the function of proteins. Concatenated 
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phosphorylation/dephosphorylation reactions are an important intracellular signaling 
mechanism that can turn on and off many biological processes, such as cell differentiation, 
proliferation and survival (Ehrnhoefer et al., 2011, Wang et al., 2010).  
 Phosphorylation pathways also play a significant role in mutant Htt cleavage, 
aggregation and toxicity. Htt can be phosphorylated at serine 421 by protein kinase Akt-1 and 
by the serum and glucocorticoid-induced kinase, SGK (Humbert et al., 2002, Rangone et al., 
2004). Akt-1-mediated phosphorylation reduces caspase cleavage of mutant Htt, leading to a 
decreased formation of large inclusions and lower toxicity in HD models, both in vitro and in 
vivo (Humbert et al., 2002, Pardo et al., 2006, Warby et al., 2009), while SGK inhibits mutant 
Htt toxicity in striatal neurons (Rangone et al., 2004). Another crucial kinase involved in HD 
pathogenesis is the cyclin-dependent kinase 5 (Cdk5), which can reversibly interact with 
serines 434, 1181, 1201 (Anne et al., 2007, Luo et al., 2005). Phosphorylation of Htt at serine 
434 has been shown to reduce Htt cleavage by caspase 3 at residue 513 and to attenuate 
aggregation (Luo et al., 2005). Constitutive phosphorylation of all three Cdk5 sites confers 
neuroprotective properties against mutant Htt toxicity (Anne et al., 2007, Luo et al., 2005).  
 
Figure 3. Structure of Huntingtin exon 1 and its phosphorylation sites. Httex1 contains an N-terminal region 
of 17 amino acids (NT17 domain) preceding a polyglutamine (PolyQ) tract and a Proline-rich region of 50 amino 
acids (PRR) on the C-terminal side of the polyglutamine tract. The NT17 domain can be phosphorylated at 
threonine (T) or serine residues (S), as indicated in yellow. 
The NT17 domain has three sites that can be modified by phosphorylation: threonine 3 
(Thr3 or T3), serine 13 (Ser13 or S13) and serine 16 (Ser16 or S16) (Figure 3).  Aiken et al. 
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(2009) showed that the phosphorylation of Thr3 occurs in vivo and affects the behavior of 
mutant Htt. Mimicking Thr3 phosphorylation alters Htt aggregation, enhancing its propensity 
to form aggregates in striatal progenitor cells and increasing the levels of insoluble Htt species 
in a Drosophila HD model. In contrast, phosphorylation resistant mutants show a slight 
decrease in aggregation propensity, whereas both phosphomimic and phosphoresistant Thr3 
mutations significantly reduce the neurodegeneration caused by mutant Htt in vivo (Aiken et 
al., 2009). Phosphorylation at Ser13 and Ser16 dramatically decreases Htt inclusion formation 
in a mammalian cellular model of the disease, and affects the alpha-helical conformation of 
the NT17 domain, targeting Htt to the nucleus (Atwal et al., 2011). Similarly, another study 
indicates that a constitutively phosphorylated state of Ser16 promotes the nuclear 
accumulation of Htt N-terminal fragments and reduces their affinity for the nuclear pore 
complex Tpr (Havel et al., 2011). Casein kinase-2 (CK2) inhibitors can reduce NT17 
phosphorylation and result in greater mutant Htt toxicity, suggesting a protective role of Ser13 
and Ser16 phosphorylation (Atwal et al., 2011). IKK, a kinase involved in inflammatory 
response, directly phosphorylates Htt at Ser13 and activates Htt clearance through 
proteosomal and lysosomal degradation mechanisms. Furthermore, the phosphorylation of 
Ser16 is facilitated by previous phosphorylation of Ser13 by IKK (Thompson et al., 2009). To 
address the importance of Ser13 and Ser16 phosphorylation in vivo, Gu et al. (2009) 
developed BACHD mice expressing Ser13 and Ser16 phosphomimic and phosphoresistant 
mutant Htt. Behavioral features of the disease, including motor and psychiatric deficits, are 
abolished when both serines are mutated to a phosphomimic residue. Moreover, mice 
expressing phosphomimic Ser13/Ser16 mutations show an impressive phenotype without 
aggregates in striatum and cortical layers of the brain, and have a later onset for 
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neurodegenerative events. Phosphoresistant mutants do not show any effect on behavior or 
histopathology of HD mice (Gu et al., 2009). 
Since the NT17 domain plays a key role in HD pathogenesis, understanding the 
phosphorylation pathways involved in the post-translational modification of these residues 
could provide insight into novel strategies for HD treatment. However, how NT17 is 
phosphorylated and how this event regulates Htt oligomerization and toxicity remain poorly 
understood. 
 
1.4. Bimolecular fluorescence complementation (BiFC) as a model for the 
study of Htt oligomerization in living cells 
 Most proteins can be split in two fragments that do not retain the original activity of 
the protein but can recover it when they are brought together in certain conditions (Kerppola, 
2008). This property of proteins is called protein complementation, and it is widely used for 
biological assays since its discovery in 1958 (Richards, 1958). A complementation assay with 
a fluorescent protein, the green fluorescent protein (GFP), was first developed for the study of 
protein-protein interactions in bacteria (Ghosh et al., 2000). Two years later, fluorescence 
complementation was implemented for the analysis of protein-protein interactions in 
mammalian cells, and the method was named bimolecular fluorescence complementation 
(BiFC) assay (Hu et al., 2002). Since then, BiFC has been used in several model organisms, 
enabling the direct visualization of protein interactions in living cells and providing a 
powerful technique for genetic or pharmacological screens. This assay is based on the 
formation of a fluorescence complex when two proteins of interest, fused to non-fluorescent 
fragments of a reporter protein, interact with each other and reconstitute the activity of the 
reporter protein (Herrera et al., 2012, Goncalves et al., 2010). 
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 The BiFC system has also proven to be a useful tool for the study of aberrant protein 
dimerization and oligomerization in the context of neurodegenerative disorders. We and 
others have recently developed BiFC models for the visualization and study of toxic 
misfolding proteins in living cells, including alpha-synuclein (Outeiro et al., 2008), huntingtin 
(Herrera et al., 2011, Lajoie and Snapp, 2010), APP (Chen et al., 2006) and tau protein (Chun 
et al., 2011). The system developed by Herrera et al. (2011) is based on the fusion of Httex1 
to two non-fluorescent halves of the Venus fluorescent protein, a third generation variant of 
the yellow fluorescent protein YFP. When huntingtin dimerizes, the Venus halves are brought 
together and reconstitute the functional fluorophore (Figure 4A). Fluorescence is then directly 
proportional to the amount of oligomeric species within cells, and can be measured by 
conventional methods, such as flow cytometry or microscopy. Herrera et al. (2011) showed 
that Htt monomers, oligomeric species and large inclusions are visually distinguishable in 
living mammalian cells. Monomeric species do not produce fluorescence, whereas oligomers 
are observed as a homogeneously distributed fluorescence and large inclusions as localized 
foci of intense fluorescence (Herrera et al., 2011) (Figure 4B). Dimers and oligomers are 
indistinguishable by this method and we will refer to both as oligomeric species throughout 
the thesis. Moreover, this system allows the quantification of cell-to-cell transmission of 
mutant Htt by flow cytometry (Herrera et al., 2011), and the identification of molecular 
modifiers of Htt aggregation (Herrera and Outeiro, 2012). In summary, these data indicate 
that the Htt BiFC system is a promising tool for the search of novel molecular targets for HD 
therapeutics and other neurodegenerative disorders involving protein misfolding and 
aggregation. 
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Figure 4. Schematic representation of the BiFC cellular model used for the visualization of mutant Httex1 
oligomeric species in living mammalian cells. (A) Httex1 is fused to two non-fluorescent halves of the Venus 
fluorescent protein. When Htt dimerizes, the Venus halves are brought together and reconstitute the functional 
fluorophore, emitting fluorescence that can be easily measured by conventional methods. (B) In this model, 
monomers do not show fluorescence; dimers and oligomers show a homogeneously distributed fluorescence in 
the subcellular compartment where they are formed; and larger inclusions are observed as brighter regions with 
different morphologies that “scavenge” fluorescence from the rest of the cell. Scale bar, 20 µm. 
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2. Objectives 
 The main goal of this study is to understand how NT17 phosphorylation regulates the 
oligomerization, aggregation and toxicity of mutant Htt. In order to address this question, we 
used the Httex1-Venus BiFC system recently developed in our laboratory (Herrera and 
Outeiro, 2012, Herrera et al., 2011) to produce a series of point mutants of the NT17 domain. 
These mutations affect the phosphorylatable residues of this domain (Thr3, Ser13 and Ser16) 
and mimic the phosphorylation and dephosphorylation of such residues. The oligomerization, 
aggregation and toxicity of phosphomutant constructs will be then compared to their non-
mutated counterpart. 
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3. Methods 
3.1. Generation of NT17 phosphomutants from Htt-Venus BiFC constructs 
The Htt-Venus BiFC cellular model recently developed in our group was used as a 
starting point for the production of the NT17 phosphomutant constructs mentioned above. We 
generated six different phosphomutant (phosphomimic and phosphoresistant mutants) 
constructs using the original 103QHtt-Venus1 and 103QHtt-Venus2 BiFC plasmids as a 
template (Figure 5). For the sake of simplicity, we will refer to both 103QHtt-Venus1 and 
103QHtt-Venus2 BiFC plasmids as 103QHtt-Venus BiFC constructs throughout the present 
thesis. These constructs encoded for Htt exon1 fused to two non-fluorescent halves of the 
Venus fluorescent protein (Venus 1, amino acids 1-158, and Venus 2, amino acids 159-238). 
Venus halves are located in the C-terminal part of Htt exon1, a location that was found 
optimal in previous work from our laboratory (Herrera et al., 2011). The expression of the 
fusion proteins is constitutively regulated by the cytomegalovirus promoter (CMV), which 
induces high levels of expression. A bovine growth hormone polyA sequence is located after 
the Htt-Venus fusion proteins for mammalian expression. The polyglutamine region of Htt 
contains 103 glutamines, a tract length that is correlated with early-onset, extremely severe 
cases of HD. 103QHtt-Venus BiFC constructs also contain ampicillin- and neomycin-
resistance sequences in order to select those bacteria or mammalian cells that carry the 
constructs. 
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Figure 5. Schematic representation of the phosphomimic and phosphoresistant mutants. To evaluate the 
role of T3, S13 and S16 phosphorylation in mammalian cells, these residues were mutated to aspartate (T3D, 
S13D, S16D) or alanine (T3A, S13A, S16A). Aspartate mimics phosphorylated residues and alanine is not 
phosphorylatable, mimicking a constitutively unphosphorylated residue.  
 
Single point mutations were independently induced in the three phosphorylatable 
residues (Threonine 3, Serine 13 and Serine 16) within the N-terminus of 103QHtt-Venus 
BiFC plasmids. The substitution of these phosphorylatable residues to Alanine (Ala, A) or 
Asparagine (Asp, D) confers them phosphoresistant or phosphomimic properties, respectively 
(Aiken et al., 2009, Gu et al., 2009). The negative charge of aspartic acid resembles 
phosphorylation, mimicking a constitutively phosphorylated state. On the other hand, the 
absence of the hydroxyl group (OH-) in alanine makes it virtually impossible to 
phosphorylate the residue, mimicking a constitutively unphosphorylated state. The general 
procedure for the generation of the phosphomutant constructs is explained below and 
illustrated in the following workflow (Figure 6).  
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Figure 6.  Workflow for the generation of NT17 phosphomutant constructs.  
 
3.1.1. Design of mutagenesis primers 
 Eight pairs of mutagenesis primers (8 forward and 8 reverse) were designed by means 
of the PrimerX free software (http://www.bioinformatics.org/primerx/) (Table I). The original 
codons corresponding to phosphorylatable amino acids (Thr3, Ser13, Ser16) were replaced by 
GCC or GAC mutant codons, which encode for Alanine (Ala, A) or Asparagine (Asp, D), 
respectively (Figure 7). 
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Figure 7. Selected mutant triplets for the production of phosphoresistant or phosphomimic mutations. To 
induce the single point mutations in the phosphorylatable residues Thr3, Ser13 and Ser16, their original codons 
(ACC, TCC, AGC) were substituted by selected codons that encode for the amino acids Ala (GCC) or Asp 
(GAC). 
 
3.1.2. Site-directed mutagenesis  
 PCR-based site-directed mutagenesis was used to produce the NT17 phosphomutants 
from the 103QHtt-Venus BiFC templates. Briefly, a PCR was carried out using the 
PfuTurbo® DNA Polymerase (Stratagene, La Jolla, CA, USA) (1.25 U), the 103QHtt-Venus 
BiFC templates (10 ng) and the mutagenesis primers (62.5 ng, each primer), and the 
following conditions: 1 min at 95ºC, 18 cycles x [50 s at 95ºC, 50 s at 60ºC, 8 min at 68ºC] 
and 10 min at 68ºC. The forward and reverse oligonucleotide primers used to introduce the 
specific point mutations are summarized in Table I. 
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Table I. Primers for site-directed mutagenesis. In red are represented the specific nucleotide mutation that will 
confer phosphoresistant properties to the residue, and in green, the selected nucleotide substitution for the 
generation of phosphomimic mutants. 
Mutation 
Htt-Venus 
BiFC plasmid 
template 
Forward Primer Reverse Primer 
T3A 
Htt-Venus1 
5' 
ACCGCCATGGCGGCCCTGGAAAAGCTG
ATGAA 3' 
5' 
TTCATCAGCTTTTCCAGGGCCGCCATGGC
GGT 3' 
Htt-Venus2 
5' 
ACTTAAGATGGCGGCCCTGGAAAAGCT
G 3' 
5' CAGCTTTTCCAGGGCCGCCATCTTAAGT 
3' 
S13A 
Htt-Venus1 
Htt-Venus2 
5' GAAGGCCTTCGAGGCCCTCAAAAGCT 
3' 
5' AGCTTTTGAGGGCCTCGAAGGCCTTC 3' 
S16A 
Htt-Venus1 
Htt-Venus2 
5' 
CGAGTCCCTCAAAGCCTTCCAACAGCA
GC 3' 
5' 
GCTGCTGTTGGAAGGCTTTGAGGGACTCG 
3' 
T3D 
Htt-Venus1 
5' 
ACCGCCATGGCGGACCTGGAAAAGCTG
AT 3' 
5' 
ATCAGCTTTTCCAGGTCCGCCATGGCGGT 
3' 
Htt-Venus2 
5' 
TTAAACTTAAGATGGCGGACCTGGAAA
AGCTGATGAA 3' 
5' 
TTCATCAGCTTTTCCAGGTCCGCCATCTTA
AGTTTAA 3' 
S13D 
Htt-Venus1 
Htt-Venus2 
5' 
ATGAAGGCCTTCGAGGACCTCAAAAGC
TTCC 3' 
5' 
GGAAGCTTTTGAGGTCCTCGAAGGCCTTC
AT 3' 
S16D 
Htt-Venus1 
Htt-Venus2 
5' 
TCGAGTCCCTCAAAGACTTCCAACAGC
AGCA 3' 
5' 
TGCTGCTGTTGGAAGTCTTTGAGGGACTC
GA 3' 
 
3.1.3. DpnI digestion and Bacterial Transformation  
 The resulting mutagenesis reactions were incubated with DpnI (Promega, Madison, 
WI, USA) at 37
o
C, for 2 hours. The DpnI endonuclease cleaves specifically methylated and 
hemimethylated DNA. DNA isolated from most E.coli strains is methylated and therefore 
susceptible to DpnI digestion. However, the mutagenesis PCR product is the result of an in 
vitro synthesis reaction, and it has not been in contact with any type of methylase. As a 
consequence, it is not methylated and not susceptible to DpnI digestion. This property of DpnI 
allows for the selective digestion of the DNA template (methylated) and the selection of the 
mutated constructs synthesized de novo (not methylated). The digested DNA solutions that 
theoretically contain only the mutant plasmids were then transformed into thermocompetent 
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bacteria, following a Heat-Shock Long-Term protocol. The mutant plasmids were mixed with 
thawed competent bacteria and then incubated for 30 min on ice. Heat-shock of bacteria cells 
was performed by placing the tubes on a heat-block for 45 s, at 42
o
C. The tubes were then 
immediately placed on ice for 2 min, and the resulting solutions incubated in 300 μl of liquid 
Luria Broth (LB) 1X medium [1% w/v Tryptone; 0.5% w/v Yeast extract; 171 mM NaCl] 
without antibiotics for 1 hour at 37
o
C in agitation (200 rpm). The transformed bacteria were 
seeded on LB/Agar 1X [1% w/v Tryptone; 0.5% w/v Yeast extract; 171 mM NaCl; 1.5% w/v 
Agar] petri dishes containing 100 μg/ml of ampicillin as selection antibiotic and incubated 
overnight at 37
o
C. 
 
3.1.4. Extraction and purification of DNA mutated plasmids 
 In order to obtain enough plasmid DNA for extraction and purification, clones were 
grown in agitation (200 rpm) in 4 ml of liquid LB 1X medium [1% w/v Tryptone; 0.5% w/v 
Yeast extract; 171 mM NaCl] containing 100 μg/ml of ampicillin at 37oC overnight. Plasmid 
DNA was then extracted by means of the Zyppy
TM
 Plasmid Miniprep Kit (Zymo Research, 
Irvine, CA, USA) following manufacturer’s instructions.  
 
3.1.5 Confirmation of the point mutations within NT17 domain  
 After extraction, DNA was quantified in a Nanodrop 2000 (Thermo Fisher Scientific 
Inc., West Palm Beach, FL, USA) and sequenced by means of external DNA sequencing 
services (Stabvida, Monte da Caparica, Setúbal, PT) to confirm the point mutations. The 
analysis of sequencing results was carried out by means of the Sequence Scanner Software 
v1.0 (Applied Biosystems, Life Technologies, Carlsbad, CA, USA) and the comparison of 
sequences was performed using the Basic Local Alignment Search Tool 
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(http://blast.ncbi.nlm.nih.gov/). Positive clones were stored as glycerol stocks at -80
o
C for 
future use. 
 
3.2. Experiments in mammalian cells 
 The six phosphomutant constructs were tested for their behavior in cultured cells in 
comparison to the original, non-mutated (103Q) and to wt (25Q) Htt-Venus BiFC constructs 
(Figure 8). The experiments were carried out in Human H4 glioma cells, which were 
maintained and seeded in suitable culture conditions and transfected with the different 
combinations of plasmids. Twenty-four hours after transfection, the effect of the mutations on 
huntingtin’s oligomerization and aggregation was evaluated by flow cytometry, fluorescence 
microscopy, native-PAGE immunoblotting and filter trap assays. The presence, number, 
morphology and size of Htt aggregates were quantified by microscopy. Finally, the toxicity of 
the different Htt versions was evaluated by means of the LDH release assay (Clontech 
Laboratories Inc., Mountain View, CA, USA).  
 
Figure 8. Testing the behavior of Htt-Venus BiFC mutant constructs in H4 cells. Cells were transfected with 
the phosphomutant (phosphomimic or phosphoresistant mutants), non-mutated (103QHtt-Venus) or wt (25QHtt-
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Venus) BiFC pairs of plasmids. Twenty-four hours later, transfected cells expressing various Htt constructs were 
analyzed for fluorescence levels, aggregation, oligomerization and cell viability by means of several purpose-
specific methods/techniques. 
 
3.2.1. Cell Culture 
Human H4 glioma cells (ATCC HTB-148, LGC Standards, Barcelona, Spain) were 
maintained in OPTI-MEM I (Gibco, Invitrogen, Barcelona, Spain) supplemented with 10% 
fetal bovine serum (FBS) and 1% of a penicillin/streptomycin commercial antibiotic mixture 
(Gibco, Invitrogen, Barcelona, Spain), under controlled conditions of  temperature and CO2 
(37
o
C, 5% CO2). For all the experiments, cells were counted and seeded at a density of 10.000 
cells/cm
2
. Depending on the analytical method, cells were seeded on different types of plates. 
The density was maintained among the different sizes of plates in order to obtain comparable 
results with different techniques. For flow cytometry and toxicity assays, cells were grown on 
6-well plates (35 mm per well diameter, Techno Plastic Cultures AG, Switzerland) and 
seeded in duplicate for each experimental group (2 wells per group). For microscopy, cells 
were seeded on glass- bottom 35 mm dishes (10 mm glass surface diameter, MatTek 
Corporation, Ashland, MA, USA). For protein extraction (PAGE and filter trap assays) cells 
were seeded in 100 mm dishes (Techno Plastic Cultures AG, Switzerland), respectively. 
Twenty-four hours later, X-tremeGene 9 DNA transfection reagent (Roche diagnostics, 
Mannheim, Germany) was used to transiently transfect cells with the different combinations 
of plasmids, according to the manufacturer’s instructions. We and others have observed that 
103QHtt expression is much less efficient than 25QHtt expression, resulting in impaired 
protein levels when cells are transfected with the same amount of plasmid. Such expression 
differences cause biased experimental results, 25QHtt being more toxic and producing more 
aggregates than 103QHtt. In order to correct this, 103QHtt-Venus (phosphomutants and non-
mutated plasmids) and 25QHtt-Venus BiFC plasmids were used in an approximate proportion 
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of 1:6, as previously described (Herrera et al., 2011). Twenty-four hours after transfection, 
cells were handled according to the requirements of each analytical method. 
 
3.2.2. Flow cytometry  
The fluorescence intensity of transfected cells was determined by flow cytometry. 
Cells were washed once with phosphate buffer saline (PBS) [1 mM KH2PO4; 155 mM NaCl; 
3 mM Na2HPO4-7H2O; manufactured without Ca
2+
, Mg
2+ 
or phenolsulfonphthalein (PSP)] 
(Gibco, Invitrogen, Barcelona, Spain), trypsinized (0.05 % w/v, 37
o
C, 5 min) and collected 
into BD Falcon Round-Bottom Tubes (BD Biosciences, San Jose, CA, USA). Cells were then 
resuspended in PBS at room temperature and analyzed by means of a LSR Fortessa flow 
cytometer (Beckton Dickinson, Franklin Lakes, NJ, USA). Ten thousand cells were analyzed 
per experimental group. The FlowJo software (Tree Star Inc., Ashland, OR, USA) was used 
for data analysis and representation.  
 
3.2.3. Microscopy and Image Analysis 
All images of fluorescent living cells were acquired using an Axiovert 200M widefield 
fluorescence microscope equipped with a CCD camera (Carl Zeiss MicroImaging GmbH, 
Germany). Pictures of a total of 50-100 cells per experimental group were taken and then 
analyzed by means of the ImageJ free online software (http://rsbweb.nih.gov/ij/). The 
percentage of cells with aggregates was calculated by dividing the total number of cells with 
aggregates by the total number of transfected cells. The average number of aggregates per cell 
was calculated by dividing the total number of aggregates in all cells by the total number of 
cells with aggregates. The different types of aggregates were classified in three size categories 
(<1μm, 1-3μm, >3μm), and the percentage of aggregates from each category was calculated 
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by dividing the total number of aggregates of the category by the total number of aggregates 
of any size. All graphics were made by means of the GraphPad Prism 5 software (GraphPad 
Software Inc., La Jolla, CA, USA).  
 
3.2.4. Protein extraction 
For protein extraction, cells were washed once with PBS, lysed with a lysis buffer and 
scrapped directly from the plates. For denaturalizing conditions, cells were incubated with a 
triton-based lysis buffer (1% Triton X-100, 150 mM NaCl, 50 mM Tris pH 7.4) and a 
protease inhibitor cocktail tablet (Roche diagnostics, Mannheim, Germany). For native 
conditions, cells were incubated with a lysis buffer without denaturing detergents (173 mM 
NaCl, 50 mM Tris pH 7.4, 5 mM EDTA) and a protease inhibitor cocktail tablet (Roche 
diagnostics, Mannheim, Germany). In order to avoid protein degradation, cells were always 
kept on ice during the extraction procedure. The Soniprep 150 sonicator (Albra, Milano, Italy) 
was used to sonicate cells for 10 sec at 5 mA. Sonication was essential to disrupt membranes 
and to release proteins from the cellular pellet, allowing their subsequent isolation and 
detection by western blotting. Cells were then centrifuged at 10,000 x g for 10 min at 4
o
C and 
the supernatant containing the proteins was collected. Protein concentration was quantified by 
means of the BCA Protein Assay Reagent Kit (Thermo Fisher Scientific Inc., Rockford, IL, 
USA), following manufacturer’s instructions.  
 
3.2.5. Immunoblotting  
 Equals amounts of protein (15 μg) from each extract were prepared for analysis by 
western blotting under denaturing and native conditions. For denaturing conditions, loading 
buffer (200 mM Tris-HCl pH 6.8; 8% SDS; 40% glycerol; 6.3% β-mercaptoethanol; 0.4% 
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bromophenol blue) was added to the samples, which were then boiled for 5 min at 95
o
C and 
resolved on 12% SDS-polyacrylamide gel electrophoresis with SDS-containing running. For 
native conditions, SDS- and mercaptoethanol-free loading buffer (200 mM Tris-HCl pH 6.8; 
40% glycerol; 0.4% bromophenol blue) was added to the samples, and the boiling step was 
omitted. Samples were directly loaded and run on 5% Native (SDS-free)-polyacrylamide gels 
using SDS-free running buffer. Protein transfer to PVDF membranes was carried out by 
means of the Trans-Blot Turbo
TM
 Transfer Starter System (Bio-rad, Hercules, CA, USA). 
After transfer, Ponceau S staining was performed on membranes to verify protein transfer 
efficiency as well as equal sample loading. 
Membranes were blocked with 5% non-fat dry milk in Tris-HCl buffer saline-Tween 
(TBS-T) (150 mM NaCl, 50 mM Tris pH 7.4, 0.5% Tween-20) for 1 hour at room 
temperature in agitation. Membranes were incubated with a mouse monoclonal Htt antibody 
(1:500, Millipore, Billerica, MA, USA) overnight at 4
o
C in agitation; or with a mouse 
monoclonal GAPDH antibody (1:30000, Ambion, Austin, TX, USA) for 1 hour at room 
temperature in agitation. The primary antibodies were previously diluted in 5% bovine serum 
albumin (BSA) in TBS 1X (150 mM NaCl, 50 mM Tris pH 7.4) and 0.05% of sodium azide. 
Membranes were then washed 3 times in TBS-T and incubated with a secondary mouse IgG 
Horseradish Peroxidase-linked antibody (GE Healthcare Life Sciences, Uppsala, Sweden), 
previously diluted in 5% non-fat dry milk in TBS-T, under the following conditions: 1:5000 
for 2-3 hours (for Htt) or 1:40000 for 30 min (for GAPDH) at room temperature in agitation. 
Membranes were washed 3 times in TBS-T and the immunoblot signal was developed by 
enhanced chemiluminescence reagents (Millipore, Billerica, MA, USA) and exposition to 
autorradiographic films.  
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3.2.6. Filter trap assay 
 Protein extracts were obtained in native conditions, as described above, and SDS was 
added to 100 μg of each extract to a final SDS concentration of 0.4% (w/v). The samples were 
passed through cellulose acetate membranes (0.22 μm pore; GE Water & Process 
Technologies, Fairfield, CT, USA) by vacuum, using a dot blot device. Cellulose acetate 
membranes were previously incubated with PBS 1X and 1% (w/v) SDS solution. After 
filtration, wells were washed twice with PBS 1X and 1% (w/v) SDS solution, and membranes 
were then blocked, incubated with antibodies and submitted to chemiluminescence detection 
as described above. 
 
3.2.7. Toxicity assay 
A colorimetric LDH release assay was used to measure the toxicity levels of the 
different constructs. This assay is based on the measurement of the activity of lactate 
dehydrogenase (LDH), a cytosolic enzyme that is released to extracellular medium upon 
damage to the cell membrane. Therefore, extracellular levels of LDH are directly proportional 
to cell toxicity. Cells were plated in duplicate for each experimental group (2 wells of 6-well 
plates) and transfected with the different combinations of plasmids. Twenty-four hours after 
transfection, 5μl of medium were collected in triplicate from each well into a 96-well plate 
(Techno Plastic Cultures AG, Switzerland) and the LDH activity  determined by means of the 
LDH cytotoxicity detection kit (Clontech Laboratories Inc., Mountain View, CA, USA) 
following manufacturer’s instructions. The absorbance of the samples was read at 492 nm 
using the Infinite M200 plate reader (Tecan, Männedorf, Switzerland). The average 
absorbance value was calculated and released LDH activity was graphically represented in 
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arbitrary units using the GraphPad Prism 5 software (GraphPad Software Inc., La Jolla, CA, 
USA). 
 
3.2.8. Statistics 
GraphPad Prism 5 software (GraphPad Software Inc., La Jolla, CA, USA) was used to 
perform the statistical analysis. Results are shown as the average ± standard deviation of at 
least 3 independent experiments. Results were analyzed by means of a one-way ANOVA 
followed by a Tukey’s Multiple Comparison Test for comparison of averages. Results were 
considered significant only when p<0.05. 
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4. Results 
4.1. NT17 phosphomimic mutations affect mutant huntingtin 
oligomerization and aggregation 
 NT17 phosphorylation has been shown to modulate the aggregation and toxicity of 
mutant Htt (Aiken et al., 2009, Gu et al., 2009, Thompson et al., 2009). To elucidate the effect 
of NT17 phosphorylation in the oligomerization, aggregation and toxicity of mutant Htt in 
living mammalian cells, a series of 103QHtt-Venus BiFC phosphomutant constructs were 
generated as described in the Material and Methods section (Figure 5). The aggregation 
pattern of phosphomimic (T3D, S13D, S16D) and phosphoresistant (T3A, S13A, S16A) 
mutants was compared with non-mutated 103QHtt BiFC (103Q wt) constructs. The non-
mutated 103QHtt BiFC pair showed both cytosolic homogenous fluorescence (oligomers) and 
large intracellular fluorescent aggregates (inclusion bodies) (Figure 9A), confirming previous 
reports (Herrera and Outeiro, 2012, Herrera et al., 2011). Surprisingly, all cells expressing 
NT17 phosphomimic constructs showed a striking phenotype without aggregates, and the 
presence of large aggregates was completely displaced by a homogeneous cytosolic 
fluorescence (Figure 9A). These results strongly suggest that NT17 phosphorylation totally 
abolishes the formation of large Htt aggregates and favors the production of more soluble 
dimers and oligomeric species. Phosphoresistant BiFC pairs showed a phenotype very similar 
to non-mutant 103QHtt, having both diffuse fluorescence and large aggregates in the 
cytoplasm (Figure 9A). Consistently, no significant differences were observed in terms of 
number and size of Htt aggregates (Figure 9C-E). However, when cells were transfected with 
the S16A 103QHtt BiFC pair constructs, the percentage of cells with large aggregates 
increased slightly but significantly (Figure 9B). This result could indicate that the 
dephosphorylation of Serine16 increases the propensity of mutant Htt to form large 
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aggregates inside the cells. In fact, there was a tendency, not reaching statistical significance, 
of all phosphoresistant mutants to increase the number of aggregates per cell (Figure 9C and 
9D). The size of the aggregates did not change (Figure 9E). 
A 
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B                                  C
 
 
Figure 9. Phosphorylation of NT17 residues abolishes the accumulation of large Htt aggregates in H4 cells. 
(A) Cells were transfected with the indicated pairs of BiFC constructs, and the generation of large aggregates 
was evaluated by means of fluorescence microscopy. The 103QHtt pair of constructs typically shows large 
aggregates in the cytosol. While the phenotype of phosphoresistant mutants resemble the 103QHtt wt phenotype, 
the phosphomimic mutants showed homogeneous fluorescence in the cytosol, with a total absence of aggregates. 
Scale bar, 20 μm. (B-E) Quantitative analyses of microscopy pictures showed that the phosphoresistant mutation 
at Ser16 increases the percentage of cells with aggregates (B), but no significant differences were observed for 
the other parameters and phosphomutants. #, Significant versus non-mutated 103QHtt BiFC constructs, p<0.05.  
 
In order to measure the levels of oligomeric species and to determine the solubility of 
large aggregates, Native-PAGE immunoblotting and filter trap assays were performed (Figure 
10). As previously described,  25QHtt wt forms single-size oligomeric species but not SDS-
insoluble aggregates, and 103QHtt generates oligomeric species of variable size and large 
E D 
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insoluble aggregates (Herrera and Outeiro, 2012, Herrera et al., 2011). Cells transfected with 
phosphomimic mutants did not show SDS-insoluble aggregates in filter trap assays, 
confirming microscopy results (Figure 10, FT, top blots). The absence of SDS-insoluble 
aggregates was accompanied by an increase in the amount of oligomeric species in the case of 
the S16D mutant, but not in the T3D and S13D mutants (Figure 10, Native-PAGE). 
Interestingly, alanine amino acid substitution at Ser13 and Ser16 also led to a decrease in 
SDS-insoluble aggregates versus non-mutated 103QHtt. Alanine substitution at Thr3 did not 
have an effect on the production of SDS-insoluble aggregates. Unlike phosphomimic mutants, 
phosphoresistant BiFC pairs showed lower levels of oligomers and a more defined protein 
band.  
 
Figure 10. Phosphorylation of NT17 residues affects Htt oligomerization and the formation of large 
aggregates.  Filter trap (FT) assays were consistent with microscopy results, showing that phosphomimic 
mutants do not produce SDS-insoluble aggregates. In the case of the S16D mutant, there is also a striking 
increase in the production of oligomeric species, as can be observed in native-PAGE conditions. Htt wt (25Q) 
did not produce SDS-insoluble aggregates or large amounts of oligomeric species. When transfected together 
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phosphomimic 103QHtt-V1 BiFC mutant and non-mutated 103QHtt-V2 BiFC constructs showed similar levels 
of SDS-insoluble aggregates but a mixed pattern in terms of oligomerization. 
 
Although phosphomimic and phosphoresistant mutations resulted in different effects 
in terms of oligomerization as determined by Native-PAGE, flow cytometry analyses showed 
that both types of mutants had similar levels of fluorescence (Figure 11). Cells transfected 
with either phosphomimic or phosphoresistant mutants showed similar numbers of fluorescent 
cells versus non-mutated 103QHtt BiFC constructs, but a significantly increase in number of 
fluorescent cells when compared to 25QHtt wt BiFC constructs (Figure 11A-C). The reasons 
for the inconsistency between Native-PAGE and flow cytometry results are currently under 
study in our laboratory, and will be addressed in the Discussion section of the present thesis.  
 Taken together, these results suggest that the phosphorylation of the NT17 domain 
modulates mutant Htt aggregation and oligomerization. 
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Figure 11. Phosphomimetic and phophoresistant mutations have no effect on fluorescence levels in H4 
cells. (A) Cells transfected with phosphomimic or phophoresistant mutants showed similar number of 
B C 
A 
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fluorescent cells comparing with non-mutant 103QHtt BiFC pair constructs, but an increase number of cells with 
fluorescence when compared with 25QHtt wt BiFC pair constructs. (B) Representative comparative histograms 
of flow cytometry analyses of the FL1 quadrant shown in A. (C) Graph showing the number of fluorescent cells 
in the different groups. *, Significant versus 25QHtt BiFC constructs, p<0.05. 
 
4.2. Co-expression of phosphomimic mutants with non-mutated BiFC 
constructs recovers Htt aggregation pattern  
 In normal conditions the pool of Htt molecules would not be completely 
phosphorylated, but there would be a mixed population of phosphorylated and 
unphosphorylated Htt molecules. To further investigate the relationship between 
phosphorylated and unphosphorylated pools of Htt molecules both phosphomimic 103QHtt-
Venus 1 plasmids and non-mutated 103QHtt-Venus 2 BiFC plasmids were co-transfected into 
H4 cells. The different combinations of plasmids showed a mixed phenotype in terms of 
aggregation (Figure 12). Most particularly, cells showed aggregates (Figure 12A), but in 
lower proportion than the non-mutant 103QHtt pair of constructs (Figure 12B). This indicates 
that phosphorylated Htt can still form aggregates in the presence of unphosphorylated Htt. 
The combination of 103QHtt T3D with non-mutant 103Q led to a marked decrease in the 
number of aggregates per cell (Figure 12C), but an increase in the percentage of aggregates 
larger than 3 μm (Figure 12E). This increase was also accompanied by a decrease in the 
proportion of aggregates smaller than 1μm (Figure 12E), suggesting that the T3D mutant 
promotes the aggregation of the smallest aggregates into larger aggregates when 
unphosphorylated Htt is present. Consistently, the expression of T3D mutants together with 
non-mutated Htt constructs also showed a total absence of cells with more than 25 aggregates, 
a significant decrease in the percentage of cells containing 10-25 aggregates and a significant 
increase in cells showing less than 10 aggregates (Figure 12D). On the other hand, co-
transfection of S13D or S16D mutants and non-mutated constructs had no effect on the 
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number and size of aggregates (Figure 12C and 12E). However, the combination of S13D 
mutant with 103QHtt wt led to a lower percentage of cells showing 10-25 aggregates (Figure 
12D).    
 
 
            
 
D E 
A 
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Figure 12. Co-expression of 103QHtt wt and phosphomimic mutants BiFC constructs recovers Htt 
aggregation pattern. (A) H4 cells were co-transfected with phosphomimic 103QHtt-Venus1 and non-mutated 
103QHtt-Venus2 BiFC plasmids. These combinations showed mixed phenotypes in terms of aggregation. Scale 
bar, 20 μm. (B-E) Quantitative analyses of microscopy pictures for each combination of constructs. B, 
Percentage of cells that showed aggregates versus number of fluorescent (transfected) cells. C, Average number 
of aggregates per cell. D, Percentage of cells showing less than 10 aggregates, between 10 and 25 and more than 
25, versus the total number of cells showing aggregates. E, Percentage of aggregates smaller than 1 µm, between 
1 and 3 µm and larger than 3 µm, versus the total number of aggregates.  #, Significant versus 103QHtt wt BiFC 
pair, p<0.05. 
 
Filter trap assays were consistent with microscopy results, showing that cells 
transfected with the different combinations of plasmids (phosphomimic 103QHtt-V1 mutants 
and non-mutated 103QHtt-V2) recovered the presence of SDS-insoluble aggregates (Figure 
13). On the other hand, native-PAGE immunoblotting analyses showed a mixed 
oligomerization pattern. S13D or S16D 103Q / 103Q wt combinations produced higher 
amounts of oligomeric species, while T3D 103Q / 103Q wt combinations showed similar 
levels of oligomeric species than the 103QHtt wt pair of constructs. Again, flow cytometry 
analyses did not showed differences between the different combinations (Figure 14).  
These results indicate that NT17 phosphorylation is a rate-limiting event in the balance 
between Htt oligomerization and aggregation in living cells. If the whole Htt pool is 
phosphorylated there are no aggregates and the balance shifts towards the production of 
oligomeric species. On the other hand, if there is a mixed population of molecules, the 
phosphorylation of the different NT17 residues produces different patterns of oligomerization 
and aggregation. 
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Figure 13. The combination of 103QHtt wt and phosphomimic mutants BiFC constructs results in 
different patterns of oligomerization. When transfected together, phosphomimic 103QHtt-V1 BiFC mutant 
and non-mutated 103QHtt-V2 BiFC constructs showed similar levels of SDS-insoluble aggregates but a mixed 
pattern in terms of oligomerization.  
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Figure 14. Co-transfection of 103QHtt wt BiFC constructs and phosphomimic mutants has no effect on 
fluorescence levels of H4 cells. (A, C) Cells were co-transfected with phosphomimic 103QHtt-Venus1 and non-
mutated 103QHtt-Venus2 BiFC plasmids. These combinations showed similar number of fluorescent cells 
comparing with the 103QHtt wt BiFC pair, but an increased number of fluorescent cells when compared with the 
25QHtt BiFC pair. (B) Representative histograms of flow cytometry analyses (from quadrant FL1 in A) showing 
equal levels of fluorescence between the different experimental groups.*, Significant versus 25QHtt BiFC pair, 
p<0.05. 
 
4.3. Toxicity is not associated with Htt oligomerization or aggregation  
 Growing evidence indicates that the oligomeric soluble intermediates formed during 
aggregation process are the most toxic species (Arrasate et al., 2004, Bodner et al., 2006, 
Kuemmerle et al., 1999). Furthermore, phosphorylation pathways have been shown to 
modulate the toxicity of mutant Htt in vitro by affecting its aggregation dynamics (Atwal et 
al., 2011, Gu et al., 2009). In order to test whether phosphomimic or phosphoresistant 
A 
B C 
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mutations had any effect in mutant Htt toxicity, LDH release assays were performed in H4 
cells twenty-four hours after transfection (Figure 15). Either phosphoresistant or 
phosphomimic mutations at Thr3 did not modify mutant Htt toxicity (Figure 15A), while 
phosphoresistant mutations at Ser13 caused lower toxicity levels (Figure 15B). Both Ser16 
phosphomutants showed a slight protective effect versus the non-mutated 103QHtt BiFC pair 
(Figure 15C). Interestingly, when 103QHtt wt and phosphomimic Htt BiFC constructs were 
combined, the toxicity was significantly decreased in all cases.  The largest effect was 
obtained with the combination containing the S16D phosphomutant, which decreased mutant 
Htt toxicity to wt levels (Figure 15D). 
These results are not correlated to the levels of Htt oligomeric species or aggregation. 
For example, the T3A phosphoresistant BiFC pair showed lower levels of oligomeric species 
(Figure 10), but did not decrease toxicity (Figure 15A). Conversely, while the S16D 
phosphomimic BiFC pair produced a striking increase in oligomeric species (Figure 10), it 
significantly prevented toxicity (Figure 15C). All phosphomimic pairs completely abolished 
the generation of large aggregates (Figure 9A). However, only the S16D pair prevented 
toxicity (Figure 15C). The combinations of 103QHtt wt and phosphomimic BiFC constructs 
produced diverse patterns of oligomerization and aggregation (Figure 12 and 13), but all of 
them prevented significantly toxicity (Figure 15D). Our results strongly suggest that there is 
not a direct association between Htt oligomerization, aggregation and toxicity. 
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Figure 15. Toxicity is not associated with oligomerization or aggregation of Htt phosphomutants. (A) H4 
cells were transfected with different combination of plasmids and cell toxicity was determined by LDH release 
assay. T3 phosphomutants did not modify the toxicity of mutant Htt. (B) Phosphoresistant, but not 
phosphomimetic mutations at Serine13 were significantly protective. (C) Both phosphoresistant and 
phosphomimetic mutations at Serine16 partially decrease toxicity. (D) Co-expression of phosphomimic mutants 
and single non-mutated 103QHtt BiFC constructs showed to be protective against mutant Htt toxicity, especially 
the S16 phosphomimic mutants, that decreases the toxicity to wild-type Htt levels. *Significant versus 25QHtt 
BiFC pair constructs, #Significant versus non-mutated 103QHtt BiFC pair constructs, p<0.05. 
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Table II. Summary of results 
 
BiFC constructs Fluorescence 
SDS-insoluble 
aggregates 
Oligomeric 
species 
Toxicity 
C
o
n
tr
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ls
 
25QHtt pair 
+ - + - 
103QHtt pair 
+++ +++ +++ +++ 
P
h
o
sp
h
o
r
e
si
st
a
n
t 
m
u
ta
n
ts
 
T3A 103QHtt pair 
+++ +++ ++ +++ 
S13A 103QHtt pair 
+++ ++ ++ ++ 
S16A 103Q Htt pair 
+++ ++ ++ ++ 
P
h
o
sp
h
o
m
im
ic
 
m
u
ta
n
ts
 
T3D 103QHtt pair 
+++ - +++ +++ 
S13D 103QHtt pair 
+++ - +++ +++ 
S16D 103QHtt pair 
+++ - ++++ ++ 
M
ix
tu
r
e
s 
T3D 103Q/103Q wt 
+++ +++ +++ ++ 
S13D 103Q/103Q wt 
+++ +++ ++++ ++ 
S16D 103Q/103Q wt 
+++ +++ ++++ + 
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5. Discussion 
In the present work, we showed that the phosphorylation of NT17 at any of its three 
phosphorylatable residues completely abolishes mutant Htt aggregation and alters its 
oligomerization pattern (Figure 9A and Figure 10, FT, top blots). Previous studies reported 
that amino acid substitution within the NT17 region alters the aggregation dynamics of 
mutant Htt, suggesting that the first 17 amino acids play a critical role in the intrinsic structure 
of the protein (Atwal et al., 2011, Gu et al., 2009, Mishra et al., 2012). Our results are 
consistent with the absence of large inclusions observed in the striatum and cortex of 
S13D/S16D phosphomimic HD mice (Gu et al., 2009). They also showed that double 
phosphoresistant or phosphomimic Ser13/Ser16 mutations confer distinct biophysical 
properties to the domain, changing its hydrophobicity and thereby affecting protein stability. 
Phosphoresistant serine-to-alanine substitutions increase the hydrophobicity of the residues 
and enhance the aggregation rate of Htt, whereas phosphomimic serine to aspartic acid 
substitutions decrease hydrophobicity and delays the aggregation process (Gu et al., 2009). 
Interestingly, the S16D mutant also show a striking increase in the amount of more soluble 
intermediate species (Figure 10, Native-PAGE), suggesting that the phosphorylation of this 
residue could redirect aggregation down a different assembly pathway. Previous kinetic 
studies showed that NT17 phosphorylation reduces fibrillization and causes the accumulation 
of intermediate aggregation products, resulting in both reduced aggregation kinetics and 
altered aggregate morphologies (Gu et al., 2009, Thakur et al., 2009). 
The absence of large aggregates upon NT17 phosphorylation could also involve a 
greater activity of proteostasis mechanisms and molecular chaperones. This is supported by 
the fact that NT17 phosphorylation but not its desphosphorylation enhances the clearance of 
mutant Htt via lysosome-autophagy or ubiquitin-proteasome systems (Thompson et al., 2009). 
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Large intracellular aggregates are more common in the areas of the brain most affected by 
HD, such as the striatum. In HD-affected areas the levels of NT17 phosphorylation appear to 
be lower than in less compromised areas (Aiken et al., 2009). Moreover, the phosphorylation 
level is polyQ length-dependent, where longer polyQ tracts are associated with less 
phosphorylation, especially in HD-susceptible cells. These observations are consistent with 
our results and suggest that NT17 phosphorylation could be associated with a more efficient 
clearance of Htt aggregates.  
In contrast to phosphomimic mutants, phosphoresistant mutants have a tendency to 
increase Htt aggregation (Figure 9A-D), which is consistent with previous in vitro reports 
(Atwal et al., 2011, Gu et al., 2009, Thakur et al., 2009). The aggregation-promoting effect of 
dephosphorylated Htt is further demonstrated by the fact that mixing phosphomimic mutants 
with non-mutated, expanded 103QHtt completely reversed the phosphomimic phenotype 
(Figures 12 and 13). This indicates that dephosphorylated Htt has a dominant, counteracting 
effect on phosphorylated Htt, promoting aggregation. However, filter trap results showed that 
S13A and S16A mutants had lower levels of SDS-insoluble aggregates when compared with 
their non-mutated counterpart, whereas T3A did not affect the production of insoluble Htt 
species (Figure 10, FT, top blots). Moreover, NT17 dephosphorylation induces a decrease in 
the levels of Htt soluble oligomeric species (Figure 10, Native-PAGE). These results suggest 
that the dephosphorylation of Ser13 or Ser16 maintains normal morphology of mutant Htt 
aggregates, but modifies the biophysical properties of Htt and probably their interaction with 
cellular components.  
The analyses of oligomeric species by flow cytometry (Figures 11 and 14) and Native-
PAGE (Figures 10 and 13, Native-PAGE) appeared to be inconsistent. In our model, 
fluorescence levels are expected to be directly proportional to the amount of oligomeric 
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species within cells. However, while phosphomutants showed similar fluorescence levels by 
flow cytometry (Figure 11), Native-PAGE immunoblots showed striking changes in the levels 
of oligomeric species in some of the phosphomutants (Figure 10, Native-PAGE). This 
inconsistency between the flow cytometry and the Native-PAGE results could be due to the 
particular features of the two different procedures. We have found two possible explanations 
for our results. First, while flow cytometry samples were whole cell cultures obtained with 
minimal processing, the immunoblotting samples were obtained from cell lysates, where the 
membranes are previously separated from the remaining cellular extract. The NT17 domain 
has a membrane binding signal that can modulate the association of Htt to the membranes of 
mitochondria, Golgi, endoplasmic reticulum, late endosomes and autophagic vesicles (Atwal 
et al., 2007, Rockabrand et al., 2007). Post-translational modifications of NT17 residues affect 
its subcellular localization and hydrophobicity. While mutations of threonine or serine 
residues to alanine would increase the hydrophobicity of Htt, inducing its association with 
membranes, mutations to aspartic acid would decrease hydrophobicity, inhibiting the 
association of Htt with membranes and increasing its levels in the aqueous fraction of the 
cytosol. Therefore, a considerable proportion of Htt could be attached to membranes and 
inside organelles, and discarded together with membrane pellets during protein isolation, in a 
way dependent of the hydrophobicity of each Htt version. This hypothesis would explain 
satisfactorily most filter trap and Native PAGE results, both the increase in oligomeric species 
shown in the S16D phosphomimic mutant and the decrease in insoluble aggregates (filter 
traps) and soluble oligomers shown in T3A, S13A and S16A phosphoresistant mutants. A 
second technical explanation is also possible. Flow cytometry results reflect the accumulated 
levels of dimers, but it is not able to discriminate if dimers further develop into oligomers or 
larger aggregates. In other words, flow cytometry is able to quantify the dimers that are 
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produced under particular conditions, but it does not provide qualitative information about 
how these dimers are associated. If this is true, then a decrease in large aggregates should be 
accompanied by an increase in oligomeric species, and viceversa. This is the case of S16D 
phosphomimic mutant and the mixtures of S13D or S16D phosphomimic mutants with non-
mutated 103QHtt. Both hypotheses are plausible, and not necessarily mutually exclusive. We 
are currently carrying out further investigations in order to test them. 
Our results strongly suggest that the effect of phosphomutants on Htt toxicity depends 
on the mutated residue and is not associated with the levels of oligomeric species or large 
inclusions. More particularly, although all phosphomimic mutants abolished the formation of 
large inclusions (Figure 9A), only the S16D mutation resulted in lower toxicity versus the 
103QHttex1 BiFC pair (Figure 15). Additionally, both S16A and S16D mutant prevented 
toxicity (Figure 15) despite their clearly different oligomerization patterns (Figure 10). 
Currently there is still an intense debate about whether inclusion bodies are toxic or protective 
species. However, there is also a considerable body of evidence that these Htt species may 
represent epiphenomena, and that different mechanisms might be at play (Imarisio et al., 
2008). Aberrant protein-protein interactions are thought to lie at the heart of cytotoxicity in 
the context of most neurodegenerative diseases (Goncalves et al., 2010). A few potential 
partners that could interact with the NT17 domain and modulate Htt toxicity have recently 
appeared (Omi et al., 2008, Wang et al., 2009). Additional post-translational modifications 
may also influence Htt toxicity. Phosphorylation at Ser13 by kinase IKK promotes acetylation 
and poly-SUMOylation of NT17 lysines. Post-translational modifications could therefore 
function together as a complicated compensatory mechanism to modulate Htt stability and 
toxicity (Thompson et al., 2009).  
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Our toxicity results are not totally consistent with previous studies showing that NT17 
phosphorylation is associated with reduced toxicity (Atwal et al., 2011, Gu et al., 2009, 
Thompson et al., 2009).  The substitution of the two NT17 serines by either aspartic acid (Gu 
et al., 2009, Thompson et al., 2009) or glutamic acid (Atwal et al., 2011) decrease the toxicity 
mediated by mutant Htt. These findings are consistent with our results, which showed a 
significantly reduced toxicity when the S16D mutation was present. However, when the 
phosphomimetic mutation to aspartic acid was produced only in Ser13, no effect on mutant 
Htt toxicity was observed. Bearing in mind previous studies using double serine 
phosphomimic mutants, our results suggest that the protective effect they observe could be 
mostly due to Ser16 phosphorylation. However, we cannot exclude that a double 
phosphorylation on Ser13 and Ser16 could enhance the effect of a single phosphorylation at 
Ser16. The effect of other double or triple phosphorylations of the three NT17 
phosphorylatable residues should be further investigated. 
We also demonstrated that both S13A and S16A phosphoresistant mutants led to a 
decrease in mutant Htt toxicity. In contrast, double mutations of NT17 serines to alanine were 
previously proven to not alter the toxicity of expanded Htt (Atwal et al., 2011, Thompson et 
al., 2009). This potential inconsistency could be explained by an accumulative effect of the 
double NT17 serine phosphomimic mutants that may lead to the neutralization of the 
protective effect produced when only one serine is mutated. Additionally, we showed that 
Thr3 mutants did not modify the toxicity of mutant Htt as opposed to previous results from 
Marsh and colleagues (Aiken et al., 2009). Aiken et al. (2009) showed that both 
phosphomimetic and phosphoresistant mutations at Thr3 prevent the lethality of a Drosophila 
HD model in approximately 50% versus flies carrying non-mutated 97QHtt and reduce Htt-
mediated loss of eye photoreceptors. A possible explanation for these contradictory results 
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could be the different model organisms used. While they used an in vivo model and measured 
the photoreceptor cell death from Drosophila’s eye, we used a neuroglioma cell line that 
provides a simpler and more stable microenvironment to better understand the role of NT17 
phosphorylation at a cellular and molecular level. Moreover, our results suggest that, when a 
phosphorylated Htt molecule interacts with an unphosphorylated Htt molecule, toxicity is 
significantly reduced (Figure 15D). While there may be a fly homolog of human Htt, we were 
unable to observe Htt expression in our H4 cells. Therefore, the protective effect of Thr3 
mutants in the Drosophila models could be due to their interaction with proteins that are not 
present in our cells, including Htt homologs, or to a different balance between phosphorylated 
and unphosphorylated pools of Htt. The effect of mixing phosphorylated and 
unphosphorylated pools on mutant Htt toxicity is independent of the residue, but is more 
remarkable when it concerns the Ser16 residue, suggesting a special role of this residue on the 
toxicity of expanded Htt. 
In this work, we provide new insight about the relationship between phosphorylated 
and unphosphorylated pools of Htt molecules in living cells and how their interaction control 
Htt oligomerization, aggregation and toxicity. Furthermore, our results also contribute to the 
understanding of HD molecular and cellular pathogenic mechanisms, and to the development 
of future treatments for HD and other neurodegenerative disorders involving protein 
misfolding and aggregation. 
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6. Conclusions 
In the present study, we provide evidence that: 
1) Phosphorylation of the NT17 domain regulates the oligomerization, aggregation and 
toxicity of mutant Htt. 
2) Dephosphorylated Htt molecules could have a dominant aggregation-promoting effect 
over phosphorylated Htt molecules. 
3) The toxicity of mutant Htt is not clearly associated with its oligomerization or 
aggregation, indicating that other cellular or molecular mechanisms might be involved 
in Htt-mediated cell death. 
 
Altogether, our results support the significance of NT17 phosphorylation in HD 
pathogenesis, and highlight the potential therapeutic value of targeting Thr3, Ser13 and Ser16 
residues and the pathways that regulate their phosphorylation state. Further efforts should be 
made to elucidate the signaling pathways that modulate NT17 phosphorylation and to identify 
phosphorylation-dependent protein-protein interactions and post-translational modifications 
that regulate mutant Htt toxicity. 
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